What are Pradaxa risks?

Pradaxa is a prescription drug blood-thinning medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation (AF) not caused by a heart valve problem.

The problem with Pradaxa risks is that the FDA is evaluating post-marketing reports of serious bleeding in patients taking Pradaxa. Bleeding that may lead to serious or fatal results is a well-known complication of blood thinners. The Pradaxa drug label contains a warning about significant and sometimes fatal bleeding.

Pradaxa is eliminated by the kidneys, so kidney function should be reviewed prior to treatment to determine the appropriate dose. Kidney function should be reassessed during treatment and the dose should be adjusted following recommendations in the label.

For patients with non-valvular AF, the main alternative to Pradaxa is warfarin (Coumadin). Because warfarin has been marketed for more than 50 years and is well-known to cause bleeding, patients and healthcare professionals are not likely to report bleeding in association with warfarin.

FDA is working with Boehringer Ingelheim, the Pradaxa maker, to analyze the post-market reports for evidence of inappropriate dosing, use of interacting drugs, or other clinical factors that could lead to bleeding.

Contact Our Pradaxa Bleeding Lawyers Today »

Taking Pradaxa blood thinner is not without risks. If you or a loved one has suffered Pradaxa bleeding injury please contact us about the possibility of an unsafe drug lawsuit.